Nuwellis, Inc. (NASDAQ:NUWE – Get Free Report) was the recipient of a significant decline in short interest in September. As of September 15th, there was short interest totaling 38,092 shares, a decline of 77.4% from the August 31st total of 168,583 shares. Currently, 1.1% of the company’s shares are short sold. Based on an average trading volume of 259,674 shares, the short-interest ratio is currently 0.1 days.
Analyst Upgrades and Downgrades
NUWE has been the subject of a number of research reports. Wall Street Zen raised Nuwellis to a “hold” rating in a research note on Saturday, July 18th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Nuwellis in a report on Monday. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has an average rating of “Sell”.
View Our Latest Report on NUWE
Institutional Trading of Nuwellis
Nuwellis Stock Down 3.9%
Shares of NUWE stock traded down $0.03 on Friday, reaching $0.78. The stock had a trading volume of 147,346 shares, compared to its average volume of 3,355,834. Nuwellis has a 12 month low of $0.71 and a 12 month high of $172.90. The firm has a market capitalization of $2.83 million, a price-to-earnings ratio of -0.01 and a beta of 0.23. The firm’s 50-day moving average is $1.35 and its two-hundred day moving average is $17.35.
Nuwellis (NASDAQ:NUWE – Get Free Report) last announced its earnings results on Thursday, August 13th. The company reported ($26.64) EPS for the quarter, missing the consensus estimate of ($23.80) by ($2.84). Nuwellis had a negative return on equity of 623.14% and a negative net margin of 123.38%.The company had revenue of $1.97 million for the quarter, compared to the consensus estimate of $2.42 million.
About Nuwellis
Nuwellis, Inc (NASDAQ: NUWE) is a medical device company focused on therapies for managing fluid overload. The company develops and commercializes solutions intended to remove excess salt and water from the blood of patients who do not respond adequately to diuretics, particularly individuals with heart failure and related conditions.
Nuwellis’ principal product is the Aquadex system, a specialized ultrafiltration platform that includes a console and disposable blood circuit. The system is designed for use in hospital and other clinical settings to provide controlled fluid removal under the supervision of healthcare professionals.
The company was formerly known as CHF Solutions, Inc and adopted the Nuwellis name in 2020.
Read More
- Five stocks we like better than Nuwellis
- 3 Defense Stocks Riding Nuclear, Missile, and Aerospace Demand
- SoFi Is Bypassing the Banking Bottleneck With Stablecoin Settlement
- These 3 Overlooked Stocks Have Big Money Behind Them
- Darden Restaurants Serves Up Fresh Catalysts for a Stock Price Rally
Receive News & Ratings for Nuwellis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuwellis and related companies with MarketBeat.com's FREE daily email newsletter.
